The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Asymmetric Dimethylarginine and the Risk of Cardiovascular Events and Death in Patients With Coronary Artery Disease: Results from the Athero Gene Study
Open accessAbstract
As a competitive inhibitor of endothelial nitric oxide synthase, asymmetric dimethylarginine (ADMA) has been related to atherosclerotic disease. Little is known about the prognostic impact of baseline ADMA determination. In a prospective cohort of 1908 patients with coronary artery disease, we assessed baseline serum concentration of ADMA in 1874 consecutive patients with coronary artery disease. One hundred fourteen individuals developed the primary end point of death from cardiovascular causes or nonfatal myocardial infarction during a mean follow-up of 2.6±1.2 years. Median concentrations of ADMA levels were higher among individuals who subsequently developed the primary end point than among those who did not (0.70 versus 0.63 μmol/L; P <0.001). The risk of future cardiovascular event was associated with increasing thirds of baseline ADMA ( P for trend, <0.001) such that individuals in the highest third at entry had a hazard ratio 2.48 times higher than those in the lowest third (95% confidence interval, 1.52 to 4.06; P <0.001). This relationship remained nearly unchanged after adjustment for most potential confounders. Prediction models that simultaneously incorporated ADMA, B-type natriuretic peptide, C-reactive protein, and creatinine in addition to traditional risk factors revealed B-type natriuretic peptide (hazard ratio, 1.96; 95% confidence interval, 1.3 to 3.0; P =0.002) and ADMA (hazard ratio, 1.90; 95% confidence interval, 1.3 to 2.8; P =0.001) as the strongest risk predictors. High levels of baseline ADMA independently predict future cardiovascular risk. ADMA has prognostic value beyond traditional risk factors and novel biomarkers and might guide therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
Palmer, R. M. J., Ferrige, A. G., & Moncada, S. (1987) · Nature · doi:10.1038/327524a0 · Cited by 10,704
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine
Valkonen, V.-P., Päivä, H., Salonen, J. T., Lakka, T. A., Lehtimäki, T., Laakso, J., & Laaksonen, R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07184-7 · Cited by 562
Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease
Wang, J., Sim, A. S., Wang, X. L., Salonikas, C., Naidoo, D., & Wilcken, D. E. L. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.05.002 · Cited by 96
Cited by
Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation
Tejero, J., Shiva, S., & Gladwin, M. T. (2019) · Physiological Reviews · doi:10.1152/physrev.00036.2017 · Cited by 541
Rochette, L., Lorin, J., Zeller, M., Guilland, J.-C., Lorgis, L., Cottin, Y., & Vergely, C. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.004 · Cited by 456
Atherogenic Index of Plasma: Novel Predictive Biomarker for Cardiovascular Illnesses
Fernández-Macías, J. C., Ochoa-Martínez, A. C., Varela-Silva, J. A., & Pérez-Maldonado, I. N. (2019) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.08.009 · Cited by 458
Endothelial progenitor cells in cardiovascular disorders
Shantsila, E., Watson, T., & Lip, G. Y. H. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.050 · Cited by 413
Böger, R. H., Sullivan, L. M., Schwedhelm, E., Wang, T. J., Maas, R., Benjamin, E. J., Schulze, F., Xanthakis, V., Benndorf, R. A., & Vasan, R. S. (2009) · Circulation · doi:10.1161/circulationaha.108.838268 · Cited by 351
Metadata
- Authors
- Schnabel, R., Blankenberg, S., Lubos, E., Lackner, K. J., Rupprecht, H. J., Espinola-Klein, C., Jachmann, N., Post, F., Peetz, D., Bickel, C., Cambien, F., Tiret, L., & Münzel, T.
- Venue
- Circulation Research
- Published
- 2005-09-02
- Volume
- 97
- Issue
- 5
- Pages
- e53-9
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2169513794
- Cited by
- 378
- References
- 6
- FWCI
- 17.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Asymmetric Dimethylarginine and the Risk of Cardiovascular Events and Death in Patients With Coronary Artery Disease: Results from the Athero Gene Study. https://app.cochat.ai/papers/10.1161/01.res.0000181286.44222.61
- The paper
- Schnabel, R., Blankenberg, S., Lubos, E., Lackner, K. J., Rupprecht, H. J., Espinola-Klein, C., Jachmann, N., Post, F., Peetz, D., Bickel, C., Cambien, F., Tiret, L., & Münzel, T. (2005). Asymmetric Dimethylarginine and the Risk of Cardiovascular Events and Death in Patients With Coronary Artery Disease: Results from the Athero Gene Study. Circulation Research. https://doi.org/10.1161/01.res.0000181286.44222.61
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.